Cerebrolysin, hemorrhagic transformation, and anticoagulation timing after reperfusion therapy in stroke: <i>post hoc</i> secondary analysis of the CEREHETIS trial.
Kalinin MN, Khasanova DR · 2025 · Frontiers in pharmacology. 2025.
Study findings
In the high-risk subgroup, symptomatic hemorrhagic transformation was less frequent in the Cerebrolysin arm (hazard ratio 0.245; 95% CI 0.072–0.837). The authors also modeled changes in hemorrhage risk over time.
- Population and setting
- 238 thrombolysis-treated patients in a secondary CEREHETIS analysis
- Evidence type
- Human comparative study
- Source language
- eng
- Title source
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
Study limitations
- Post hoc analysis of an existing trial, not a new randomized comparison.
- Modeled risk thresholds do not establish a safe time to start anticoagulation; prospective validation is required.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Full-text methods and results check
Related-report group: CEREHETIS. Reports in this group are not assumed to be independent trials.
Source access and review scope
Repository full text checked for design, participants and reported outcomes; no independent reanalysis.
Recorded source-check date: 2026-10-08. This date does not imply a completed systematic review.
Citation and original source
Original source: Kalinin MN, Khasanova DR. Cerebrolysin, hemorrhagic transformation, and anticoagulation timing after reperfusion therapy in stroke: <i>post hoc</i> secondary analysis of the CEREHETIS trial. Frontiers in pharmacology. 2025. 2025.
Molekul research summary: https://molekul.io/research/refresh-41640685. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry